| Date Filed | Type | Description |
| 03/20/2019 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 03/20/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/20/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/20/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/14/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/14/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/14/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/14/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/14/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/14/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/14/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/12/2019 |
SC 13D/A
| BROADWOOD PARTNERS, L.P. reports a 0% stake in Asterias Biotherapeutics, Inc. |
| 03/08/2019 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 03/08/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 03/01/2019 |
8-K
| Quarterly results |
| 03/01/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 02/28/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 02/04/2019 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 01/24/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/24/2019 |
GN
| Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury |
| 01/04/2019 |
GN
| BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase |
| 12/06/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 12/06/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 12/04/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 11/27/2018 |
GN
| Asterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small Cell Lung Cancer |
| 11/09/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 11/09/2018 |
10-Q
| Quarterly Report for the period ended September 30, 2018 |
| 11/08/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 11/08/2018 |
SC 13D/A
| BIOTIME INC reports a 39.2% stake in ASTERIAS BIOTHERAPEUTICS, INC. |
| 11/08/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 11/08/2018 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"AGREEMENT AND PLAN OF MERGER",
"Amended and Restated Employment Agreement, by and between Asterias Biotherapeutics, Inc. and Craig Halberstadt",
"Amended and Restated Employment Agreement, by and between Asterias Biotherapeutics, Inc. and Edward Wirth, III",
"Amended and Restated Employment Agreement, by and between Asterias Biotherapeutics, Inc. and Ryan Chavez",
"BioTime Acquires Two Clinical-Stage Cell Therapy Product Candidates Addressing Significant Unmet Needs in Spinal Cord Injury and Immuno-Oncology Asterias Stockholders to Receive 0.71 Shares of BioTime for Each Share of Asterias Biotherapeutics ALAMEDA, CA and FREMONT, CA – - BioTime, Inc. , and Asterias Biotherapeutics, Inc. , today announced that they have entered into a definitive merger agreement whereby BioTime will acquire all of the remaining outstanding common stock of Asterias that are not currently owned by BioTime. Asterias stockholders will receive 0.71 shares of BioTime common shares for every share of Asterias common stock and will own approximately 16.2% of the combined company. Subject to customary closing conditions, including approval by the respective shareholders of BioT..." |
|
| 11/08/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 11/02/2018 |
GN
| Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018 |
| 10/31/2018 |
GN
| Asterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury Study |
|